01 1Taro Pharmaceutical Industries
01 1LULICONAZOLE
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2017-06-12
Pay. Date : 2017-03-29
DMF Number : 31217
Submission : 2017-03-30
Status : Active
Type : II
20
Taro Pharmaceutical Industries Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is LULICONAZOLE, with a corresponding US DMF Number 31217.
Remarkably, this DMF maintains an Active status since its submission on March 30, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 12, 2017, and payment made on March 29, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II
